Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Necrotizing Enterocolitis
Status: | Suspended |
---|---|
Conditions: | Colitis, Gastrointestinal |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | Any - 1 |
Updated: | 12/19/2018 |
Start Date: | April 2010 |
End Date: | April 2019 |
The purpose of this study is to characterize the time to maturation of neutrophil
extracellular trap(NET) formation capability in polymorphonuclear leukocytes(PMNs) isolated
from newborn premature and term infants as well as infants <1 year of age undergoing elective
surgery. This study will also determine whether NETs contribute to the pathogenesis of
necrotizing enterocolitis (NEC). We hypothesize that NET formation contributes to the
pathogenesis of NEC by inappropriately releasing degradative proteins and tissue destructive
enzymes into the inflammatory milieu of the premature infant gastrointestinal tract following
bacterial translocation. We also hypothesize that the delay in NEC development in premature
infants (3rd - 4th week of life) as compared to at-risk term infants (1st week of life)
results from a developmental delay in PMN ability to form NETs.
extracellular trap(NET) formation capability in polymorphonuclear leukocytes(PMNs) isolated
from newborn premature and term infants as well as infants <1 year of age undergoing elective
surgery. This study will also determine whether NETs contribute to the pathogenesis of
necrotizing enterocolitis (NEC). We hypothesize that NET formation contributes to the
pathogenesis of NEC by inappropriately releasing degradative proteins and tissue destructive
enzymes into the inflammatory milieu of the premature infant gastrointestinal tract following
bacterial translocation. We also hypothesize that the delay in NEC development in premature
infants (3rd - 4th week of life) as compared to at-risk term infants (1st week of life)
results from a developmental delay in PMN ability to form NETs.
Prematurely born infants are at risk for necrotizing enterocolitis (NEC), the most common
gastrointestinal emergency encountered in the newborn intensive care unit. This disease
occurs in between 5 - 10% of infants born at less than 30 weeks gestation or less than 1500
grams birth weight. In these patients, NEC routinely develops during the 3rd or 4th week of
life. NEC rarely occurs in infants born closer to term; for these patients NEC usually
develops during the 1st week of life. So far, no one has explained the inverse relationship
between gestational age at birth and the delay in NEC development.
Recently, our laboratory described for the first time an inherent deficiency of innate
immunity in newborn infants - failure of neutrophil extracellular trap formation. Neutrophil
extracellular traps or NETs are complex lattices of extracellular chromatin and DNA decorated
with anti-microbial proteins and degradative enzymes which trap and kill microbes. When the
neutrophils of newborn infants develop the ability to form NETs and whether the maturation of
NET formation correlates with development of NEC in at risk infants remains unknown.
We have therefore undertaken the following study best described as a prospective, in vitro
longitudinal cellular biology study of LPS/PAF-stimulated PMNs isolated from the cord and
peripheral blood of premature infants at risk for NEC and from term infants not considered at
risk for NEC. We will also assay for NET formation in gastrointestinal tissue samples
obtained at the time of surgery for severe NEC in enrolled prematurely born infants. These
studies are the first of their kind and aim to answer these important questions.
gastrointestinal emergency encountered in the newborn intensive care unit. This disease
occurs in between 5 - 10% of infants born at less than 30 weeks gestation or less than 1500
grams birth weight. In these patients, NEC routinely develops during the 3rd or 4th week of
life. NEC rarely occurs in infants born closer to term; for these patients NEC usually
develops during the 1st week of life. So far, no one has explained the inverse relationship
between gestational age at birth and the delay in NEC development.
Recently, our laboratory described for the first time an inherent deficiency of innate
immunity in newborn infants - failure of neutrophil extracellular trap formation. Neutrophil
extracellular traps or NETs are complex lattices of extracellular chromatin and DNA decorated
with anti-microbial proteins and degradative enzymes which trap and kill microbes. When the
neutrophils of newborn infants develop the ability to form NETs and whether the maturation of
NET formation correlates with development of NEC in at risk infants remains unknown.
We have therefore undertaken the following study best described as a prospective, in vitro
longitudinal cellular biology study of LPS/PAF-stimulated PMNs isolated from the cord and
peripheral blood of premature infants at risk for NEC and from term infants not considered at
risk for NEC. We will also assay for NET formation in gastrointestinal tissue samples
obtained at the time of surgery for severe NEC in enrolled prematurely born infants. These
studies are the first of their kind and aim to answer these important questions.
Inclusion Criteria:
1. Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤ 1500
grams or <30 weeks gestational age at birth
2. Term infants delivered at UUMC without complication, either via cesarean section or
vaginal delivery
3. Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery
within the first year of life.
Exclusion Criteria:
- No other exclusion criteria
We found this trial at
2
sites
201 Presidents Circle
Salt Lake City, Utah 84108
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Christian C Yost, MD
Phone: 801-581-7052
University of Utah Research is a major component in the life of the U benefiting...
Click here to add this to my saved trials
100 N Mario Capecchi Dr
Salt Lake City, Utah 84132
Salt Lake City, Utah 84132
(801) 662-1000
Principal Investigator: Christian C Yost, MD
Phone: 801-581-7052
Click here to add this to my saved trials